Gustel Lifescience Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 12 Year, 9 Months
- Last Filing with ROC 31 Mar 2021
- Open Charges ₹ 9.50 M
- Revenue Growth -39.57%
- Profit Growth -3169.39%
- Ebitda -69.46%
- Net Worth -21.68%
- Total Assets 27.88%
About Gustel Lifescience
Gustel Lifescience Private Limited (GLPL) is a Private Limited Indian Non-Government Company incorporated in India on 04 May 2012 and has a history of 12 years and nine months. Its registered office is in Jaipur, Rajasthan, India.
The Corporate was formerly known as Elanco Healthcare Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹9.50 M.
Sharma Pulkit and Madhukar Sharma serve as directors at the Company.
Company Details
-
Location
Jaipur, Rajasthan, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24232RJ2012PTC038821
-
Company No.
038821
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
04 May 2012
-
Date of AGM
30 Nov 2021
-
Date of Balance Sheet
31 Mar 2021
-
Listing Status
Unlisted
-
ROC Code
Roc Jaipur
Industry
Who are the key members and board of directors at Gustel Lifescience?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sharma Pulkit
|
Director | 04-May-2012 | Current |
|
Madhukar Sharma
|
Additional Director | 02-Sep-2022 | Current |
Financial Performance of Gustel Lifescience.
Gustel Lifescience Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 39.57% decrease. The company also saw a substantial fall in profitability, with a 3169.39% decrease in profit. The company's net worth observed a substantial decline by a decrease of 21.68%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Gustel Lifescience?
In 2019, Gustel Lifescience had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Sentient Formulations Private LimitedSharma Pulkit is a mutual person
Charges (Loans)
₹9.50 M
₹0
Charges Breakdown by Lending Institutions
- Bank Of Baroda : 0.95 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 15 Oct 2013 | Bank Of Baroda | ₹9.50 M | Open |
How Many Employees Work at Gustel Lifescience?
Unlock and access historical data on people associated with Gustel Lifescience, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Gustel Lifescience, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Gustel Lifescience's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
